These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9602707)

  • 61. Dysplasia in Barrett's oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproducible.
    Kaye PV; Ilyas M; Soomro I; Haider SA; Atwal G; Menon S; Gill S; Richards C; Harrison R; West K; Ragunath K
    Histopathology; 2016 Sep; 69(3):431-40. PubMed ID: 26918780
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
    Klump B; Hsieh CJ; Holzmann K; Borchard F; Gaco V; Greschniok A; Eckardt VF; Bettendorf U; Gregor M; Porschen R
    Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients.
    Dumot JA; Vargo JJ; Falk GW; Frey L; Lopez R; Rice TW
    Gastrointest Endosc; 2009 Oct; 70(4):635-44. PubMed ID: 19559428
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Barrett's esophagus: pathologic considerations and implications for treatment.
    Rice TW; Mendelin JE; Goldblum JR
    Semin Thorac Cardiovasc Surg; 2005; 17(4):292-300. PubMed ID: 16428035
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
    Polkowski W; van Lanschot JJ; Ten Kate FJ; Baak JP; Tytgat GN; Obertop H; Voorn WJ; Offerhaus GJ
    Surg Oncol; 1995 Jun; 4(3):163-71. PubMed ID: 7582189
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Improved Progression Prediction in Barrett's Esophagus With Low-grade Dysplasia Using Specific Histologic Criteria.
    Ten Kate FJC; Nieboer D; Ten Kate FJW; Doukas M; Bruno MJ; Spaander MCW; Looijenga LHJ; Biermann K;
    Am J Surg Pathol; 2018 Jul; 42(7):918-926. PubMed ID: 29697438
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inter-Observer Agreement among Pathologists Using Wide-Area Transepithelial Sampling With Computer-Assisted Analysis in Patients With Barrett's Esophagus.
    Vennalaganti PR; Naag Kanakadandi V; Gross SA; Parasa S; Wang KK; Gupta N; Sharma P
    Am J Gastroenterol; 2015 Sep; 110(9):1257-60. PubMed ID: 25916227
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Diagnosis and risk stratification of Barrett's dysplasia by flow cytometric DNA analysis of paraffin-embedded tissue.
    Choi WT; Tsai JH; Rabinovitch PS; Small T; Huang D; Mattis AN; Kakar S
    Gut; 2018 Jul; 67(7):1229-1238. PubMed ID: 28642331
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Risk of progression in Barrett's esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland.
    Huhta H; Melkko J; Kuopio T; Karttunen TJ; Helminen O
    Scand J Gastroenterol; 2022 Sep; 57(9):1024-1029. PubMed ID: 35450519
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The utility of P53 immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia.
    Januszewicz W; Pilonis ND; Sawas T; Phillips R; O'Donovan M; Miremadi A; Malhotra S; Tripathi M; Blasko A; Katzka DA; Fitzgerald RC; di Pietro M
    Histopathology; 2022 Jun; 80(7):1081-1090. PubMed ID: 35274753
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Aberrant p53 expression is associated with neoplastic progression in Barrett oesophagus diagnosed as indefinite for dysplasia.
    Chen X; Liu BL; Harpaz N; Zhu H; Polydorides AD; Liu Q
    Histopathology; 2023 Feb; 82(3):454-465. PubMed ID: 36251540
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Histological assessment & use of immunohistochemical markers for detection of dysplasia in Barrett's esophageal mucosa.
    Kinra P; Gahlot GPS; Yadav R; Baloda V; Makharia GK; Gupta SD; Das P
    Pathol Res Pract; 2018 Jul; 214(7):993-999. PubMed ID: 29764708
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry.
    Krishnamoorthi R; Lewis JT; Krishna M; Crews NJ; Johnson ML; Dierkhising RA; Ginos BF; Wang KK; Wolfsen HC; Fleischer DE; Ramirez FC; Buttar NS; Katzka DA; Iyer PG
    Am J Gastroenterol; 2017 Jun; 112(6):867-873. PubMed ID: 28374813
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A Consensus Diagnosis Utilizing Surface KI-67 Expression as an Ancillary Marker in Low-Grade Dysplasia Helps Identify Patients at High Risk of Progression to High-Grade Dysplasia and Esophaegal Adenocarcinoma.
    Lee C; Hayat U; Song K; Gravely AA; Mesa H; Peltola J; Iwamoto C; Manivel C; Bilal M; Shaheen N; Shaukat A; Hanson BJ
    Dis Esophagus; 2023 Feb; 36(3):. PubMed ID: 36190180
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Use of p53 immunohistochemistry in conjunction with routine histology improves risk stratification of patients with Barrett's oesophagus during routine clinical care.
    Tokuyama M; Geisler D; Deitrick C; Fasanella KE; Chennat JS; McGrath KM; Pai RK; Davison JM
    Histopathology; 2020 Sep; 77(3):481-491. PubMed ID: 32431062
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Meta-analysis of biomarkers predicting risk of malignant progression in Barrett's oesophagus.
    Altaf K; Xiong JJ; la Iglesia D; Hickey L; Kaul A
    Br J Surg; 2017 Apr; 104(5):493-502. PubMed ID: 28295252
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Development of a deep learning model for the histologic diagnosis of dysplasia in Barrett's esophagus.
    Faghani S; Codipilly DC; David Vogelsang ; Moassefi M; Rouzrokh P; Khosravi B; Agarwal S; Dhaliwal L; Katzka DA; Hagen C; Lewis J; Leggett CL; Erickson BJ; Iyer PG
    Gastrointest Endosc; 2022 Dec; 96(6):918-925.e3. PubMed ID: 35718071
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Surveillance for low-grade dysplastic Barrett's oesophagus: one size fits all?
    Zaninotto G; Bennett C
    World J Surg; 2015 Mar; 39(3):578-85. PubMed ID: 24919861
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Progression of Barrett's esophagus, crypt dysplasia, and low-grade dysplasia diagnosed by wide-area transepithelial sampling with 3-dimensional computer-assisted analysis: a retrospective analysis.
    Shaheen NJ; Smith MS; Odze RD
    Gastrointest Endosc; 2022 Mar; 95(3):410-418.e1. PubMed ID: 34537193
    [TBL] [Abstract][Full Text] [Related]  

  • 80. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia.
    Younes M; Ertan A; Lechago LV; Somoano JR; Lechago J
    Dig Dis Sci; 1997 Apr; 42(4):697-701. PubMed ID: 9125634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.